Adma Biologics Inc. (NASDAQ:ADMA)’s share price traded down 2.9% on Thursday . The company traded as low as $5.34 and last traded at $5.34, with a volume of 93,770 shares. The stock had previously closed at $5.50.

A number of equities analysts recently weighed in on the stock. Raymond James Financial Inc. downgraded shares of Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday, August 1st. Maxim Group downgraded shares of Adma Biologics from a “buy” rating to a “hold” rating in a research note on Monday, August 1st.

The company’s market capitalization is $69.33 million. The firm’s 50 day moving average is $6.42 and its 200-day moving average is $6.38.

Adma Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Friday, August 12th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.11. On average, analysts predict that Adma Biologics Inc. will post ($1.83) EPS for the current year.

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.